Profile
Sector:
HealthcareCountry:
United KingdomIPO:
25 July 2022Website:
http://www.haleon.comNext earnings report:
28 February 2025Last dividends:
16 August 2024Next dividends:
N/APrice
after hours | Fri, 15 Nov 2024 22:29:10 GMTAnalysts recommendations
Institutional Ownership
HLN Latest News
Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy Vistar Media's programmatic OOH technology to enhance Haleon's premium, global media strategy
Haleon plc (NYSE:HLN ) Q3 2024 Sales Conference Call October 31, 2024 5:00 AM ET Company Participants Rakesh Patel - Director of Investor Relations Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Group AG David Hayes - Jefferies Group LLC Iain Simpson - Barclays Rashad Kawan - Morgan Stanley Celine Pannuti - JPMorgan Chase & Co. Victoria Petrova - BofA Securities Karel Zoete - Kepler Cheuvreux Tom Sykes - Deutsche Bank Rakesh Patel Good morning everyone, and welcome to Haleon's Conference Call for our Third Quarter Trading Statement. I am Rakesh Patel, Director, Investor Relations, and with me today is Tobias Hestler, our CFO.
Currency fluctuations meant Haleon PLC (LSE:HLN, NYSE:HLN), the FTSE 100-listed Panadol and Sensodyne owner, saw year-on-year reported revenue by 0.6% to £2.78 billion in the third quarter. Stripping away the impact of the weaker US dollar, the consumer health giant's organic revenues increased by 6.1%.
Haleon reported a marginal fall in its third-quarter revenue on Thursday, hurt by declines in its pain relief and digestive health segments.
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has secured a $5 million milestone payment following the US launch of its flagship product, Eroxon. The payment was triggered as Haleon, the company's distribution partner, began fulfilling online pre-orders and making fast-acting erectile dysfunction gel available in American retail stores.
UBS has reiterated its buy rating on Haleon PLC (LSE:HLN, NYSE:HLN) shares after news that former parent company Pfizer Inc (NYSE:PFE, ETR:PFE) further pared down its stake in the FTSE 100-listed Sensodyne and Panadol maker. Haleon, which comprises the former consumer divisions of Pfizer and GSK PLC (LSE:GSK, NYSE:GSK), agreed on an off-market purchase of approximately £230 million worth of its own shares after Pfizer said t was cutting its stake by around £2.1 billion.
Haleon PLC (LSE:HLN, NYSE:HLN) said it has agreed to buy £230 million of its own shares from former co-parent Pfizer Inc (NYSE:PFE, ETR:PFE), which offloaded almost a $3.3 billion stake in the Sensodyne maker. The FTSE 100 consumer health group said made the purchase at a price of 308p per share.
British consumer healthcare company Haleon said on Friday it has agreed to raise its stake in its Chinese joint venture by 33% for 4.47 billion yuan ($637.35 million), taking its ownership to 88%.
The global healthcare brand gains increased transparency and control by getting closer to the sell-side of the ecosystem The global healthcare brand gains increased transparency and control by getting closer to the sell-side of the ecosystem
Haleon PLC (LSE:HLN, NYSE:HLN) has unveiled pricing for a near-£1 billion bond offering set to be carried out by its subsidiary this month. Some €750 million (£633 million) worth of Euro medium-term notes to mature in 2028 will be sold with a price of 2.875%, the FTSE 100-listed health firm announced Thursday.
What type of business is Haleon?
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
What sector is Haleon in?
Haleon is in the Healthcare sector
What industry is Haleon in?
Haleon is in the Drug Manufacturers - Specialty & Generic industry
What country is Haleon from?
Haleon is headquartered in United Kingdom
When did Haleon go public?
Haleon initial public offering (IPO) was on 25 July 2022
What is Haleon website?
https://www.haleon.com
Is Haleon in the S&P 500?
No, Haleon is not included in the S&P 500 index
Is Haleon in the NASDAQ 100?
No, Haleon is not included in the NASDAQ 100 index
Is Haleon in the Dow Jones?
No, Haleon is not included in the Dow Jones index
When was Haleon the previous earnings report?
No data
When does Haleon earnings report?
The next expected earnings date for Haleon is 28 February 2025